XML 74 R56.htm IDEA: XBRL DOCUMENT v3.23.1
Collaboration and License Agreements - Contract Liabilities - Additional Information (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Additions to deferred revenue $ 69,555 $ 3,834  
Deductions to deferred revenue recognized during the period 52,989 37,781  
Deferred revenue 301,326 284,760 $ 318,707
AbbVie Ireland Unlimited Company | CD71 Agreement      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 4,000 $ 16,100  
Deferred Revenue Recognition Maturity Year 2023    
Amgen Inc | EGFR Products      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 18,000    
Deferred Revenue Recognition Maturity Year 2026    
Amgen Inc | Amgen Other Products      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 600    
Deferred Revenue Recognition Maturity Year 2023    
Astellas Pharma Inc.      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 44,500    
Deferred Revenue Recognition Maturity Year 2026    
Bristol Myers Squibb      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 169,200    
Deferred Revenue Recognition Maturity Year 2025    
ModernaTX, Inc      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 35,000    
Deferred Revenue Recognition Maturity Year 2028    
Regeneron Pharmaceuticals, Inc      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]      
Deferred revenue $ 30,000    
Deferred Revenue Recognition Maturity Year 2026